Review
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Mar 15, 2023; 14(3): 130-146
Published online Mar 15, 2023. doi: 10.4239/wjd.v14.i3.130
Pancreatic β-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress
Phiwayinkosi V Dludla, Sihle E Mabhida, Khanyisani Ziqubu, Bongani B Nkambule, Sithandiwe E Mazibuko-Mbeje, Sidney Hanser, Albert Kotze Basson, Carmen Pheiffer, Andre Pascal Kengne
Phiwayinkosi V Dludla, Sihle E Mabhida, Carmen Pheiffer, Biomedical Research and Innovation Platform, South African Medical Research Council, Cape Town 7505, South Africa
Phiwayinkosi V Dludla, Albert Kotze Basson, Department of Biochemistry and Microbiology, University of Zululand, KwaDlangezwa 3880, South Africa
Khanyisani Ziqubu, Sithandiwe E Mazibuko-Mbeje, Department of Biochemistry, North-West University, Mmabatho 2745, South Africa
Bongani B Nkambule, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban 4000, South Africa
Sidney Hanser, Department of Physiology and Environmental Health, University of Limpopo, Sovenga 0727, South Africa
Andre Pascal Kengne, Department of Medicine, University of Cape Town, Cape Town 7500, South Africa
Andre Pascal Kengne, Non-Communicable Diseases Research Unit, South African Medical Research Council, Tygerberg 7505, South Africa
Author contributions: Dludla PV, Mabhida SE, Ziqubu K, Nkambule BB, Mazibuko-Mbeje SE, Hanser S, Basson AK, Pheiffer C, Kengne AP contributed to writing and final approval of the manuscript.
Supported by the Biomedical Research and Innovation Platform, of the South African Medical Research Council (SAMRC), and the National Research Foundation (grant No. 132534 and 141929). The content hereof is the sole responsibility of the authors and do not necessarily represent the official views of the SAMRC or the funders.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Phiwayinkosi V Dludla, PhD, Adjunct Professor, Biomedical Research and Innovation Platform, South African Medical Research Council, Francie van Zijl Drive Parow valley, Cape Town; PO Box 19070 7505 Tygerberg, Cape Town 7505, South Africa. pdludla@mrc.ac.za
Received: October 12, 2022
Peer-review started: October 12, 2022
First decision: November 6, 2022
Revised: November 26, 2022
Accepted: February 27, 2023
Article in press: February 27, 2023
Published online: March 15, 2023
Processing time: 154 Days and 3.4 Hours
Core Tip

Core Tip: Elevated markers of inflammation and oxidative stress are related to β-cell dysfunction, the intracellular defense (antioxidant) mechanisms responsible for ameliorating some of these effects are significantly depleted during type 2 diabetes (T2D). Thus, beyond lowering glucose levels like most antidiabetic drugs, future research should invest in developing therapeutic agents to ameliorate inflammation and oxidative stress to improve blood control in patients with T2D.